
Roche’s Tecentriq combo shows promise in first-line triple-negative breast cancer
pharmafile | April 1, 2019 | News story | Research and Development, Sales and Marketing | Cancer, Roche, breast cancer, pharma, tecentriq
Roche has revealed new Phase 1b data on a new Tecentriq combo, showing early promise in the first-line treatment of advanced triple-negative breast cancer (TNBC).
The findings showed that the combination of ipatasertib, Tecentriq (atezolizumab) and chemotherapy (paclitaxel or nab-paclitaxel (Abraxane [paclitaxel albumin-bound particles for injectable suspension]) delivered an objective response rate (ORR) of 73% in the study’s 26 participants, regardless of tumour biomarker status.
“We are enthusiastic about the potential of this combination in triple-negative breast cancer, an aggressive type of breast cancer,” commented Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “These early results support the contribution of ipatasertib to our combination treatment approach in TNBC and reinforce our vision to develop medicines that may benefit patients with this challenging disease.”
Roche confirmed that a multi-centre Phase 3 study into the efficacy of Tecentriq, ipatasertib, and paclitaxel in the treatment of locally advanced/metastatic triple-negative breast cancer will launch later this year.
Matt Fellows
Related Content

Bio-Sourcing and Zerion Pharma receive 1.3m euros in funding for joint breast cancer project
Bio-Sourcing and Zerion Pharma have announced that their collaboration to develop an oral form of …

Biocartis announces breast cancer research collaboration with US Mayo Clinic
Biocartis has announced a research collaboration with Mayo Clinic in the US, aiming to develop …

Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …






